Product news from the 11/21/06 news brief
Takeda Pharmaceutical has discontinued of development of its investigational compound, TAK-128 to treat peripheral diabetic neuropathy.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.